Experience
Fidelity National Information Services, Inc.; Metavante Corporation
CashEdge, Inc. and CheckFree Corp.
Finnegan client Fidelity National Information Services Inc. (FIS) successfully challenged four banking patents owned by its rival financial-services-technology provider Fiserv Inc. FIS petitioned the Patent Trial and Appeal Board (PTAB) for covered business method patent review (CBM). The PTAB said the four patents—directed to processing payment instructions, providing electronic biller notifications, and processing interbank fund-transfer transactions—cover abstract ideas that, in light of the Supreme Court’s decision on patentability in Alice Corp. v. CLS Bank International, are too abstract to be patentable. The PTAB decisions stem from a suit filed in January 2012, in which Fiserv subsidiaries CheckFree Corp. and CashEdge Inc. accused FIS and its subsidiary Metavante Corp. of infringing the patents. Following a Markman hearing, the court stayed the litigation while the PTAB reviewed the Fiserv patents.
CheckFree Corp. and CashEdge Inc. v. Fidelity National Information Services, Inc.; Metavante Corporation, 3:12-cv-00015, M.D. Fla., Judges Howard, Toomey
Fidelity National Information Services, Inc.; Metavante Corporation v. CashEdge, Inc. and CheckFree Corp., CBM2013-00028, -00030, -00031, -00032, PTAB, Judges Grossman, McNamara, Pettigrew
CashEdge, Inc. and CheckFree Corp. v. Fidelity National Information Services, Inc.; Metavante Corporation, 15-1519, -1524, -1529, -1530, Fed. Cir.
FIS successfully uses PTAB to invalidate quintessential “Business Method Patents”
Fidelity National Information Services, Inc. (FIS)
Toyota Motor Corp.
USPTO cancels all claims for Finnegan client CRS in second CBM proceeding (in favor of)
CRS Advanced Technologies
Video game maker Harmonix succeeds in invalidating asserted litigation claims using IPR
Harmonix Music Systems, Inc.
Finnegan secures jury verdict of willful infringement for ProSlide
ProSlide Technology, Inc.
Finnegan client AbbVie secures non-institution decisions for Humira® patents
AbbVie Biotechnology, Ltd
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.